Protalix BioTherapeutics, Inc. Financials

Market Capitalization ₪292.9 Million as of Jan. 1, 2023

Valuations Metrics as of May. 5, 2024

Trailing PE
Forward PE
Price to Sales TTM	₪8.82
Price to Book MRQ	₪
Enterprise to Revenue	9.06
Enterprise to EBITDA	-36.17

Financial Reports as of Dec. 31, 2022

Financials

Fiscal Year Ends	2022-12-31
Most Recent Quarter	2022-12-31
Profit Margin	-31.33%
Operating Margin	-27.32%
Return on Assets TTM	-12.57%
Return on Equity TTM	3.83%

Income Statement

Revenue TTM	₪47,638,000
Revenue per Share TTM	₪0.98
Quarterly Revenue Growth	0.80%
Gross Profit TTM	₪28,046,000
EBITDA	₪None
Net Income to Common TTM	₪-14,927,000
Diluted EPS TTM	₪-1.11
Quarterly Earnings Growth YoY	0.80%

Balance Sheet

Total Cash MRQ	₪None
Total Cash per Share MRQ	₪0.39
Total Debt MRQ	₪
Total Debt to Equity MRQ	-0.09
Current Ratio MRQ	1.38
Book Value per Share MRQ	₪-0.20

Cash Flow

Operating Cash Flow TTM	₪-19,656,000
Levered Free Cash Flow TTM	₪-14,927,000

PLX Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	57,381,000
Float Shares	50,562,210
Avg 10 Volume	88,161
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	15.53%
% Held by Institutions	8.64%

Stock Price Summary

Beta	1.47
Fifty Two Week Low	₪330.00
Fifty Two Week High	₪780.00
Fifty Two Week Change	0.62%
Day 50 MA	₪602.06
Day 200 MA	₪438.21

Dividends and Splits

Forward Annual Dividend Rate	₪
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	₪0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2019-12-22